Alliqua Biomedical Inc (NASDAQ:ALQA) shares have plunged by 31% after the company announced the pricing of an underwritten public offering of 9.375 million shares at $0.40 a piece. Rodman & Renshaw was the underwriter of the offering and Alliqua Biomedical Inc (NASDAQ:ALQA) intends to use the net proceeds for general corporate and working capital purposes, along with for paying its monthly obligations under the company’s credit agreement with Perceptive Credit Opportunities Fund. Given the nano-cap size of the Alliqua’s market cap, along with its rather small average dollar volume, raising over $3 million likely needed a big discount for investors to commit, and Alliqua shares fell today because of that dynamic.
What Does The Smart Money Sentiment Say?
At Insider Monkey, we’ve developed an investment strategy that has delivered market-beating returns over the past 12 months. Our strategy identifies the 100 best-performing funds of the previous quarter from among the collection of 700+ successful funds that we track in our database, which we accomplish using our returns methodology. We then study the portfolios of those 100 funds using the latest 13F data to uncover the 30 most popular mid-cap stocks (market caps of between $1 billion and $10 billion) among them to hold until the next filing period. This strategy delivered 39.7% gains over the past 12 months and outperformed the 24.1% gain enjoyed by the S&P 500 ETFs. Our enhanced small-cap hedge fund strategy returned more than 45% over the last 12 months and outperformed SPY by more than 30 percentage points over the last 4.5 years (see details here).
In terms of smart money sentiment, not many elite funds owned Alliqua Biomedical Inc (NASDAQ:ALQA) at the end of the fourth quarter. Of the 742 top institutions that we track, 4 owned shares of Alliqua Biomedical Inc (NASDAQ:ALQA) at the end of the fourth quarter, unchanged from that of the previous quarter. Joseph Edelman‘s Perceptive Advisors kept its stake the same at 1.9 million shares while Hal Mintz‘s Sabby Capital trimmed its stake by 17% to 1.1 million shares.
The Bottom Line
Alliqua Biomedical Inc (NASDAQ:ALQA) shares are down due to a secondary offering.